Overview

Inqovi Maintenance Therapy in Myeloid Neoplasms

Status:
Recruiting
Trial end date:
2024-08-01
Target enrollment:
Participant gender:
Summary
This research is being done to see if the drug Inqov is effective in reducing the chance of myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) relapsing after standard of care stem cell transplant. - This research study involves the study drug Inqovi, which is a combination of the drugs decitabine and cedazuridine.
Phase:
Phase 1
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborators:
Taiho Oncology, Inc.
Taiho Pharmaceuticals
Treatments:
Decitabine